GleamWall
中文EN

TLPH TALPHERA, INC.

Pharmaceutical Preparations · Nasdaq · SEC CIK 1427925 · Fiscal year ends 12/31

Financial factors as of 2026-06-30 (2026Q2), TTM = sum of the last four quarters

Growth

TTM revenue YoY-96.3%
TTM net income YoY-33.4%
TTM EPS YoY—
Revenue 3-yr CAGR—
Net income 3-yr CAGR—

Margins

Gross margin—
Operating margin-1,474,700.0%
Net margin-1,507,600.0%
FCF margin—
EBITDA margin—

Returns

ROE-143.4%
ROA-69.6%
ROIC (approx.)-172.6%
Asset turnover0.00x

Leverage & solvency

Liabilities / assets46.3%
Debt / equity0.00x
Current ratio4.29x
Interest coverage—

Cash quality & payout

Operating cash flow / net income0.81x
Accruals ratio-13.0%
Payout ratio—
Capex / revenue—

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item FY20252025-12-31FY20242024-12-31
Income statement
Revenue$28,000$0
R&D expense$6.03M$6.72M
SG&A expense$7.48M$8.53M
Operating income-$13.48M-$15.25M
Interest expense—$0
Income tax$0$0
Net income-$14.29M-$13.00M
EBITDA—-$15.25M
EPS (basic)-0.34-0.50
EPS (diluted)——
Balance sheet
Cash & equivalents$5.89M$8.86M
Short-term investments$14.49M$0
Current assets$20.90M$9.42M
Intangibles$8.82M$8.82M
Total assets$29.72M$18.24M
Current liabilities$3.81M$2.65M
Total liabilities$12.68M$10.23M
Shareholders' equity$17.04M$8.00M
Shares outstanding49.33M17.03M
Cash flow statement
Operating cash flow-$11.36M-$12.68M
Capital expenditure—$0
Free cash flow—-$12.68M
Investing cash flow-$14.35M$3.78M
Financing cash flow$22.74M$12.04M
Depreciation & amortization—$0
Stock-based compensation$699,000$989,000

Free plan shows the latest 2 periods; Pro shows all 20 🔒

· This company does not report gross profit in XBRL.

· This company reports EPS only by share class (e.g. class A/B), so it is shown as —.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.